Mindfulness-Based Art Therapy for Cancer Patients

This study has been completed.
Sponsor:
Information provided by:
National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier:
NCT00034970
First received: May 2, 2002
Last updated: August 17, 2006
Last verified: July 2006
  Purpose

The purpose of this study is to determine whether cancer patients who receive the mindfulness-based art therapy (MBAT) program demonstrate improvement in health-related quality of life, a reduction in stress-related symptoms, and enhanced coping responses.


Condition Intervention
Cancer
Behavioral: Mindfulness-based at therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Educational/Counseling/Training
Official Title: Mindfulness-Based Art Therapy for Cancer Patients

Resource links provided by NLM:


Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Estimated Enrollment: 114
Study Start Date: April 2002
Estimated Study Completion Date: December 2003
Detailed Description:

Psychosocial interventions, especially supportive-expressive group therapies, have been associated with significant improvements in health status, quality of life and coping behaviors, in patients with cancer. The purpose of the proposed pilot research study is to investigate a newly developed group therapy for cancer patients, MBAT. This proposed, randomized, controlled study follows a successful preliminary investigation of MBAT conducted at Thomas Jefferson University Hospital. MBAT integrates known benefits of art therapy, group therapy, and mindfulness-based stress reduction. Each of these fundamentally different modalities has documented usefulness in the treatment of cancer patients. The multi-modal approach is designed to enhance both the supportive and expressive aspects of the group experience. The study will be done with 96 patients who have a variety of cancer types. Participants will be matched for age and assigned randomly to either the MBAT experimental group or a non-intervention control group. Both groups will continue to receive their usual oncologic/medical care. The MBAT program consists of eight weekly meetings of two and one half-hours in length. At the end of the eight weeks, participants in the control group will be crossed over to the experimental intervention arm for an additional eight weeks. Participants will be assessed pre- and post-intervention on measures of health-related quality of life, psychological distress, and coping, using standardized outcome instruments (SF-36, SCL-90-R and COPE). Our long-term goal is to collect sufficient data to determine the overall efficacy of this promising intervention and to identify which patients are particularly likely to benefit from MBAT.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion:

  • Diagnosis of cancer or cancer recurrence within the past 2 years.
  • Able to tolerate 8 weekly groups, 2 1/2 hours in length

Exclusion:

  • Less than 4 months from original or recurrent diagnosis or beyond 2 years
  • Physically unable to attend groups
  • Non-stabilized major mental disorder
  • Children
  • Comprehension of written and spoken English at a level of less than 4th grade.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00034970

Locations
United States, Pennsylvania
Thomas Jefferson University Hospital/Kimmel Cancer Center
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Investigators
Principal Investigator: Daniel A. Monti, MD Thomas Jefferson University
Study Director: Caroline Peterson, MA Thomas Jefferson University
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00034970     History of Changes
Other Study ID Numbers: R21 AT000683-01
Study First Received: May 2, 2002
Last Updated: August 17, 2006
Health Authority: United States: Federal Government

Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
alternative medicine
art
cancer
combination cancer therapy
creative-expression
group therapy
holistic
human therapy evaluation
meditation
neoplasm /cancer chemotherapy
coping
gender difference
outcomes research
psychological aspect of cancer
psychological stressor
quality of life
racial /ethnic difference
stress management
support
behavioral /social science research
patient oriented research

ClinicalTrials.gov processed this record on August 27, 2014